Compare Stocks: LVTX, LUCD, MDWD, and TNXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LUCD Lucid Diagnostics	$0.81 -2.5%	$0.92	$0.75 ▼ $1.63	$167.88M	1.1	1.10 million shs	780,366 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A
MDWD MediWound	$13.93 +0.7%	$13.65	$12.52 ▼ $20.03	$177.88M	0.14	100,494 shs	56,600 shs
TNXP Tonix Pharmaceuticals	$9.90 +0.4%	$11.82	$9.40 ▼ $25.52	$169.11M	1.74	428,590 shs	342,238 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LUCD Lucid Diagnostics	0.00%	+5.13%	-16.68%	-21.33%	-19.81%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+9.43%
MDWD MediWound	0.00%	+3.28%	+9.32%	-8.22%	-22.64%
TNXP Tonix Pharmaceuticals	0.00%	-9.29%	-27.45%	-22.67%	-59.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LUCD Lucid Diagnostics	$0.81 -2.5%	$0.92	$0.75 ▼ $1.63	$167.88M	1.1	1.10 million shs	780,366 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A
MDWD MediWound	$13.93 +0.7%	$13.65	$12.52 ▼ $20.03	$177.88M	0.14	100,494 shs	56,600 shs
TNXP Tonix Pharmaceuticals	$9.90 +0.4%	$11.82	$9.40 ▼ $25.52	$169.11M	1.74	428,590 shs	342,238 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LUCD Lucid Diagnostics	0.00%	+5.13%	-16.68%	-21.33%	-19.81%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+9.43%
MDWD MediWound	0.00%	+3.28%	+9.32%	-8.22%	-22.64%
TNXP Tonix Pharmaceuticals	0.00%	-9.29%	-27.45%	-22.67%	-59.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	419.73% Upside
LVTX LAVA Therapeutics	1.00	Sell	N/A	N/A
MDWD MediWound	2.50	Moderate Buy	$33.00	136.90% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	147.47% Upside

Current Analyst Ratings Breakdown

Latest LVTX, LUCD, MDWD, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	MDWD MediWound	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/16/2026	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LUCD Lucid Diagnostics	$4.71M	34.77	N/A	N/A	($0.31) per share	-2.60
LVTX LAVA Therapeutics	$4.99M	9.17	N/A	N/A	$1.06 per share	1.64
MDWD MediWound	$16.96M	10.55	N/A	N/A	$3.40 per share	4.10
TNXP Tonix Pharmaceuticals	$13.11M	12.95	N/A	N/A	$19.17 per share	0.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$0.86	N/A	N/A	N/A	N/A	-107.63%	-35.06%	N/A
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest LVTX, LUCD, MDWD, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/12/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LUCD Lucid Diagnostics	N/A	1.33	1.31
LVTX LAVA Therapeutics	N/A	12.27	12.27
MDWD MediWound	N/A	2.32	2.09
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LUCD Lucid Diagnostics	74.01%
LVTX LAVA Therapeutics	N/A
MDWD MediWound	46.83%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
LUCD Lucid Diagnostics	6.90%
LVTX LAVA Therapeutics	9.50%
MDWD MediWound	9.20%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LUCD Lucid Diagnostics	82	203.24 million	189.22 million	No Data
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
MDWD MediWound	121	12.85 million	11.67 million	Optionable
TNXP Tonix Pharmaceuticals	142	17.15 million	16.81 million	Not Optionable

LVTX, LUCD, MDWD, and TNXP Headlines

Recent News About These Companies

Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell

September 26 at 1:23 AM | marketbeat.com

Tonix Pharmaceuticals Holding Corp (TNXP)

September 23, 2026 | in.investing.com

InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA(R) Medicare Coverage to 32 Million Lives

September 22, 2026 | financialcontent.comF

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

September 22, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

September 22, 2026 | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head to Head Analysis

September 21, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)

September 16, 2026 | theglobeandmail.com

Tonix Pharmaceuticals Holding Corp. (TNXP)

September 15, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

September 11, 2026 | marketbeat.com

Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst

September 10, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Tyra Bioscience (TYRA) and Becton Dickinson (BDX)

September 9, 2026 | theglobeandmail.com

Tonix Names Englese Chief Commercial Officer To Expand TONMYA Reach

September 9, 2026 | rttnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving Average - What's Next?

September 9, 2026 | marketbeat.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | finance.yahoo.com

Tonix Pharma Appoints New Chief Commercial Officer

September 8, 2026 | tipranks.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | globenewswire.com

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

September 2, 2026 | globenewswire.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

September 1, 2026 | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, LUCD, MDWD, and TNXP Company Descriptions

Lucid Diagnostics NASDAQ:LUCD

$0.81 -0.02 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+0.91%)

As of 07:30 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LAVA Therapeutics NASDAQ:LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

MediWound NASDAQ:MDWD

$13.93 +0.09 (+0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$14.14 +0.21 (+1.54%)

As of 07:55 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Tonix Pharmaceuticals NASDAQ:TNXP

$9.90 +0.04 (+0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$9.97 +0.07 (+0.70%)

As of 07:58 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, LUCD, MDWD, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, LUCD, MDWD, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, LUCD, MDWD, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, LUCD, MDWD, and TNXP Company Descriptions

Lucid Diagnostics NASDAQ:LUCD

LAVA Therapeutics NASDAQ:LVTX

MediWound NASDAQ:MDWD

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, LUCD, MDWD, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, LUCD, MDWD, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, LUCD, MDWD, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, LUCD, MDWD, and TNXP Company Descriptions

Lucid Diagnostics NASDAQ:LUCD

LAVA Therapeutics NASDAQ:LVTX

MediWound NASDAQ:MDWD

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools